Octreotide LAR for the treatment of acromegaly

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 6, 2008, Pages 783-793

  Valette, Sophie ^a   Serri, Omar ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Acromegaly; Growth hormone; IGF I; Octreotide LAR; Somatostatin

Indexed keywords

ANGIOPEPTIN; BIM 23A760; CABERGOLINE; DOPAMINE DERIVATIVE; GROWTH HORMONE; LANREOTIDE AUTOGEL; LONG ACTING DRUG; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ACROMEGALY; BINDING AFFINITY; BRADYCARDIA; CANCER INHIBITION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE RELEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOPHYSIS ADENOMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; OPTIMAL DRUG DOSE; PROTEIN SECRETION; REVIEW; SINGLE DRUG DOSE; VALVULAR HEART DISEASE;

ACROMEGALY; ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; OCTREOTIDE; TREATMENT OUTCOME;

EID: 48949117159     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.6.783     Document Type: Review

References (88)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9
2. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003;63:2473-99
3. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2007; [Epub ahead of print]
4. Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558-73
5. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41
6. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-9
7. Ritchie CM, Atkinson AB, Kennedy AL, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990;59:55-62
8. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab, 2008;93:61-7
9. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102
10. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4
11. Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly. a five-year prospective study. J Clin Endocrinol Metab, 2007;92:4271-7
12. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115:527-32
13. Burt MG, Ho KK. Newer options in the management of acromegaly. Intern Med J 2006;36:437-44
14. Serri O, Somma M, Comtois R, et al. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 1985;61:1185-9
15. Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord 2008;9:67-70
16. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-91
17. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005;62:210-6
18. Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary 2008; [Epub ahead of print]
19. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-7
20. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90:4483-8
21. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003;88:3105-12
22. Mandarino L, Stenner D, Blanchard W, et al. Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature 1981;291:76-7
23. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42
24. Patel YC. Somatostatin and its receptor Family. Front Neuroendocrinol 1999;20:157-98
25. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67
26. Lania A, Mantovani G, Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Mol Cell Endocrinol 2007
27. Hu C, Yi C, Hao Z, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004;3:726-30
28. Bousquet C, Puente E, Buscail L, et al. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001;47(Suppl 2):30-9
29. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984;59:1148-51
30. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40
31. Saveanu A, Gunz G, Guillen S, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83:258-63
32. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-5
33. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45:27-30
34. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99
35. Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment For acromegaly. J Clin Endocrinol Metab 1995;80:3267-72
36. Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-7
37. Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-6
38. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-8
39. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9
40. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86-91
41. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658-61
42. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74
43. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73 44 Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90:6290-5
44. Barlier A, Pellegrini-Bouiller I, Gunz G, et al. Impact of gap oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999;84:2759-65
45. Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001;86:3809-14
46. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1:105-14
47. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006;64:342-51
48. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86
49. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001;55:477-83
50. Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoe and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004;151:309-15
51. Colao A, Marzullo P, Cuocola A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003;58:169-76
52. Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 2006;65:626-30
53. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-63
54. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10
55. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acomegaly with octreotide LAR: along-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
56. Casarini AP, Pinto EM, Jallad RS, et al. Dissociation between tumor shrinkage ant hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29:826-30
57. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92:1592-9
58. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-40
59. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56:65-71
60. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63
61. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68
62. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-9
63. Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromega]y requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-24
64. Stewart PM, Stewart SE, Clark PM, Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 1999;50:295-9
65. Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008;158:19-25
66. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996;45:72-4
67. Abe T, Ludecke DK. Effects of preoperative actreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-45
68. Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acts Endocrinol (Copenh) 1993;129(Suppl 1):18-20
69. Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104:899-906
70. Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 2005;147:485-93
71. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6
72. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92
73. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide L.A.R. Eur J Endocrinol 2004;150:473-80
74. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150:489-95
75. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67:512-9
76. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-1 in patients with acromegaly. Chin Endocrinol (Oxf) 2007
77. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8
78. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15
79. van der Lely AJ, Kopchick JJ. Growth hormone receptor antagonists. Neuroendocrinology 2006;83:264-8
80. Strasburger CJ, Buchfelder M, Droste M, et al. Experience from the German pegvisomant observational study. Horm Res 2007;68(Suppl 5):70-3
81. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-6
82. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006;91:121-8
83. Novartis, octreotide LAR. Available from: http://www.rxlist.com
84. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Chin North Am 2008;37:101-22, viii
85. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-41
86. Ben-Shlomo A, Melmed S. Pasireotide: a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing s disease. IDrugs 2007;10:885-95
87. Emery PT, Higgs NB, Warhurst AC, et al. Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein. Br J Pharmacol 2002;135:1443-8
88. Available from: wwww.chemblink.com/structures/51110-01-1.gif.